Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Cancer Project Team of China Center for Evidence-Based Traditional Chinese Medicine, Beijing, 100053, China.
Chin J Integr Med. 2022 Oct;28(10):930-938. doi: 10.1007/s11655-022-3465-3. Epub 2022 Mar 3.
Through showing the full picture of double-arm controlled clinical research and systematic review evidence in the field of orally administrated Chinese herbal medicine (CHM) for treatment of lung cancer, to provide a reference for future clinical research and to indicate a direction for future systematic reviews.
A comprehensive search of clinical controlled studies was performed regarding orally administered CHM treatment for lung cancer published from January 1970 to September 2020. The language was restricted to Chinese and English. Relevant data were extracted, the quality of systematic reviews was evaluated, and the research evidence was visually displayed.
Randomized controlled trials were the most common type of research design. The research sample sizes were typically small. Oral CHM showed certain curative advantages in treating lung cancer. The key stages in oral CHM intervention for lung cancer are chemotherapy, radiotherapy, and late palliative treatment. The advantageous outcomes of oral CHM treatment of lung cancer are the short-term efficacy, quality of life, and adverse reactions. The perioperative stage, overall survival, pharmacoeconomic evaluation, and Chinese medicine decoctions are weak research areas.
CHM has staged and therapeutic advantages in treating lung cancer. The overall methodological quality is poor, and the level of evidence requires improvement. It is necessary to carry out large-scale, standardized, and higher-quality research in the superior and weak areas of CHM treatment of lung cancer.
通过展示口服中药治疗肺癌的双臂对照临床研究和系统评价证据全貌，为今后的临床研究提供参考，为系统评价指明方向。
检索 1970 年 1 月至 2020 年 9 月发表的关于口服中药治疗肺癌的临床对照研究，语言限定为中、英文。提取相关数据，评价系统评价的质量，并对研究证据进行可视化展示。
研究设计以随机对照试验最为常见，样本量通常较小。口服中药治疗肺癌具有一定的疗效优势，主要集中在化疗、放疗及晚期姑息治疗阶段，优势结局体现在近期疗效、生活质量及不良反应方面，围手术期、总生存期、药物经济学评价及中药方剂是研究薄弱环节。
中药治疗肺癌具有阶段性和治疗优势，但整体方法学质量较差，证据水平有待提高，有必要在中药治疗肺癌的优势和薄弱环节开展大规模、规范化、高质量的研究。
